Back to top

cell-therapy: Archive

Zacks Equity Research

GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel

Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.

BMYPositive Net Change GILDPositive Net Change ACLXNegative Net Change